Increased access to contraception is one of the best ways to build strong economies, create healthy families, and advance the sexual and reproductive health and rights of women and adolescent girls. The self-injectable contraceptive subcutaneous DMPA (DMPA-SC)* is an innovative method that can dramatically expand access and choice when offered as part of a broad method mix. Available in more than 55 countries around the world, more than 35 of which offer self-injection, DMPA-SC is easy to use, requires minimal training, and is an important addition to family planning service delivery channels in both the public and private sectors.
The Injectables Access Collaborative (AC) provides data-driven technical assistance, coordination, resources, and tools to ensure that women and girls have increased access to DMPA-SC and self-injection as part of an expanded range of contraceptive methods, delivered through informed choice programming. The AC is led by PATH in partnership with the Clinton Health Access Initiative (CHAI), inSupply Health, Jhpiego, and JSI.
Country technical assistance
Drawing from years of implementation experience and evidence, the AC team provides technical assistance (TA) to countries through three primary formats: continuous TA, short-term TA, and self-serve TA.
In addition, the AC is producing market analyses to support governments, partners, and donors working to improve access to DMPA-SC and self-injection. The AC has also developed a learning agenda to address critical questions around DMPA-SC and self-injection service delivery and will share those results along with digital resources to facilitate data collection and monitoring.
“One must keep working for methods to be accessible, for systems to be strengthened, and women must at all times have access to information to help them make their choices.”— Dr. Mareme Ndiaye, Senegal Ministry of Health and Social Action
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate, brand name Sayana® Press. Sayana Press is a registered trademark of Pfizer Inc.